Novo Nordisk Dirección

Dirección controles de criterios 3/4

Novo Nordisk's El consejero delegado es Lars Jorgensen , nombrado en Jan 2017, tiene un mandato de 7.08 años. la remuneración anual total es DKK60.10M , compuesta por 28.5% salario y 71.5% primas, incluidas acciones y opciones de la empresa. posee directamente 0.002% de las acciones de la empresa, por valor de DKK75.43M . La antigüedad media del equipo directivo y del consejo de administración es de 3 años y 5.9 años respectivamente.

Información clave

Lars Jorgensen

Chief Executive Officer (CEO)

kr.60.1m

Compensación total

Porcentaje del salario del CEO	28.5%
Permanencia del CEO	7.3yrs
Participación del CEO	0.002%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lars Jorgensen en comparación con los beneficios de Novo Nordisk?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	kr.84b
Sep 30 2023	n/a	n/a	kr.75b
Jun 30 2023	n/a	n/a	kr.67b
Mar 31 2023	n/a	n/a	kr.61b
Dec 31 2022	kr.60m	kr.17m	kr.56b
Sep 30 2022	n/a	n/a	kr.53b
Jun 30 2022	n/a	n/a	kr.51b
Mar 31 2022	n/a	n/a	kr.49b
Dec 31 2021	kr.58m	kr.17m	kr.48b
Sep 30 2021	n/a	n/a	kr.46b
Jun 30 2021	n/a	n/a	kr.44b
Mar 31 2021	n/a	n/a	kr.43b
Dec 31 2020	kr.57m	kr.14m	kr.42b
Sep 30 2020	n/a	n/a	kr.42b
Jun 30 2020	n/a	n/a	kr.41b
Mar 31 2020	n/a	n/a	kr.40b
Dec 31 2019	kr.55m	kr.14m	kr.39b
Sep 30 2019	n/a	n/a	kr.39b
Jun 30 2019	n/a	n/a	kr.38b
Mar 31 2019	n/a	n/a	kr.38b
Dec 31 2018	kr.41m	kr.11m	kr.39b
Sep 30 2018	n/a	n/a	kr.38b
Jun 30 2018	n/a	n/a	kr.39b
Mar 31 2018	n/a	n/a	kr.39b
Dec 31 2017	kr.32m	kr.9m	kr.38b

Compensación vs. Mercado: Lars($USD8.66M) está por encima de la media de empresas de tamaño similar en el mercado Danish ($USD3.55M).

Compensación vs. Ingresos: La compensación de Lars ha sido consistente con los resultados de la empresa en el último año.

CEO

Lars Jorgensen (57 yo)

7.3yrs

Permanencia

kr.60,100,000

Compensación

Mr. Lars Fruergaard Jorgensen has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member of Management Board. Mr. Jorgensen served as Deputy Chair of the...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lars Jorgensen	President	7.3yrs	kr.60.10m	0.0021% DKK 80.1m
Karsten Knudsen	Executive VP	6.2yrs	kr.21.50m	0.000010% DKK 384.9k
Henrik Wulff	Executive VP of Product Supply	no data	kr.22.00m	0.000060% DKK 2.3m
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	kr.21.30m	0% DKK 0
Martin Lange	Executive VP of Development & Member of the Management Board	3.3yrs	kr.20.90m	sin datos
Marcus Schindler	EVP of Research & Early Development	3.1yrs	kr.20.90m	sin datos
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	sin datos	0.0024% DKK 90.8m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	sin datos	sin datos
Ludovic Helfgott	Executive VP	no data	sin datos	sin datos
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.1yrs	sin datos	sin datos
David Moore	Executive VP of Corporate Development & Member of Management Board	1.1yrs	sin datos	sin datos
Daniel Bohsen	CVP & Head of Investor Relations	no data	sin datos	sin datos

3.2yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: NOVO BEl equipo directivo de la empresa se considera experimentado (2.8 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sylvie Gregoire	Independent Director	9.1yrs	kr.1.80m	sin datos
Helge Lund	Independent Chairman of the Board	7.1yrs	kr.3.10m	sin datos
Henrik Poulsen	Vice Chairman of the Board	3.1yrs	kr.2.00m	sin datos
Laurence Debroux	Independent Director	5.1yrs	kr.2.00m	sin datos
Martin MacKay	Independent Director	6.1yrs	kr.1.70m	sin datos
Andreas Fibig	Independent Director	6.1yrs	kr.1.40m	sin datos
Kasim Kutay	Non-Independent Director	7.1yrs	kr.1.20m	sin datos
Christina Law	Independent Director	2.1yrs	kr.1.30m	sin datos
Liselotte Hyveled	Employee Representative Director	2.1yrs	kr.800.00k	0.00019% DKK 7.3m
Mette Jensen	Employee Non-Independent Representative Director	6.1yrs	kr.1.20m	sin datos
Thomas Rantzau	Employee Representative Non-Independent Director	6.3yrs	kr.1.00m	sin datos
Elisabeth Christensen	Employee Representative Director	2.1yrs	kr.800.00k	sin datos

6.1yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NOVO B se considera experimentada (5.9 años de antigüedad promedio).

Novo Nordisk Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

President recently sold kr.145m worth of stock

Insider recently sold kr.10m worth of stock

Recent updates

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Final dividend of kr.6.40 announced

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Price target increased by 14% to kr.887

President recently sold kr.145m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Insider recently sold kr.10m worth of stock

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Price target increased by 7.6% to kr.672

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

First quarter 2023 earnings: Revenues exceed analyst expectations

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Price target increased by 7.6% to kr.1,106

Upcoming dividend of kr.8.15 per share at 1.3% yield

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Novo Nordisk (CPH:NOVO B) Will Pay A Larger Dividend Than Last Year At DKK8.15

Full year 2022 earnings: Revenues exceed analyst expectations

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad